Palisade Bio (PALI) Preferred Stock Liabilities (2020)
Palisade Bio's (PALI) quarterly Preferred Stock Liabilities came in at $9.5 million in Q4 2020.
Palisade Bio (PALI) Preferred Stock Liabilities (2020) Analysis & Trends
Palisade Bio (PALI) has 1 years of Preferred Stock Liabilities data on file, last reported at $9.5 million in Q4 2020.
- On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $9.5 million in Q4 2020; TTM through Dec 2020 was $9.5 million, a N/A change from a year earlier, with the FY2020 full-year figure at $9.5 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q4 2020 stood at $9.5 million.
- Over the last five years, Preferred Stock Liabilities for PALI reached as high as $9.5 million in Q4 2020 and fell as low as $9.5 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Palisade Bio | 985.76 | -132.63 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 9.50 Mn |